A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01152450
First received: June 28, 2010
Last updated: May 7, 2014
Last verified: February 2013
  Purpose

Rationale for the current trial is to demonstrate 24 hour bronchodilator efficacy and safety of tiotropium 5 µg administered once daily (in the evening) which is regarded beneficial for the compliance and convenience of the patient in comparison to placebo. Further the rationale is to evaluate efficacy and safety of tiotropium 2.5 µg administered twice daily delivered by the Respimat® inhaler in comparison to placebo and tiotropium 5 µg administered once daily (in the evening) delivered by the Respimat® inhaler in patients with moderate persistent asthma.

Rationale for the pharmacokinetic subinvestigation is to evaluate the 24 hours exposure to tiotropium in patients with moderate persistent asthma when administered 5 µg tiotropium once daily (in the evening) or 2.5 µg tiotropium twice daily.


Condition Intervention Phase
Asthma
Drug: Tiotropium 2.5 µg b.i.d
Drug: Placebo
Drug: Tiotropium 5 µg q.d.
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II, Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Administered Once Daily (in the Evening) and Tiotropium 2.5 µg Administered Twice Daily Delivered by the Respimat® Inhaler for Four Weeks Versus Placebo in Patients With Moderate Persistent Asthma

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Forced Expiratory Volume in One Second (FEV1) Area Under the Curve 0-24 Hours (AUC0-24h) Response [ Time Frame: 10 minutes (min) prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 hours (h) , 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4 ] [ Designated as safety issue: No ]
    Mixed Model Repeated Measure (MMRM) results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measurements performed in relation to evening dosing. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.


Secondary Outcome Measures:
  • Mean Pre-dose Morning Peak Expiratory Flow (PEF a.m.) Response During the Last Week on Treatment [ Time Frame: Baseline and during week 4 of each treatment period ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.

  • Mean Pre-dose Evening Peak Expiratory Flow (PEF p.m.) Response During the Last Week on Treatment [ Time Frame: Baseline and during week 4 of each treatment period ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.

  • FEV1 Area Under the Curve 0-12 Hours (AUC0-12h) Response [ Time Frame: 10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h and 11 h 50 min related to evening dose at week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

  • FEV1 Area Under the Curve 12-24 Hours (AUC12-24h) Response [ Time Frame: 10 min prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

  • Peak FEV1 Within 24 Hours Post-dose Response [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the evening trial-drug inhalation at the end of each 4 week period of randomised treatment.

  • Trough FEV1 Response [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FEV1 is defined as FEV1 value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.

  • Trough Forced Vital Capacity (FVC) Response [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FVC is defined as FVC value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.

  • FVC Area Under the Curve 0-12 Hours (AUC0-12h) Response [ Time Frame: 10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h and 11 h 50 min related to evening dose at week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

  • FVC Area Under the Curve 12-24 Hours (AUC12-24h) Response [ Time Frame: 10 min prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

  • Peak FVC Within 24 Hours Post-dose Response [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period.

  • Individual FEV1 Over Time (at Each Timepoint at Visits) Response [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.

  • Individual FVC Over Time (at Each Timepoint at Visits) Response [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.

  • Individual Peak Expiratory Flow (PEF) Over Time (at Each Timepoint at Visits) Response [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.

  • FVC Area Under the Curve 0-24 Hours (AUC0-24h) Response [ Time Frame: 10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.

  • PEF Area Under the Curve 0-24 Hours (AUC0-24h) Response [ Time Frame: 10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres/min.

  • PEF Variability Response (Last Week on Treatment) [ Time Frame: Baseline and during week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values, expressed as a percent (weekly means obtained during the last week of each period of randomised treatment will be compared).

  • Mean Number of Puffs of Rescue Medication During the Whole Day (Last Week on Treatment, Response Values) [ Time Frame: Baseline and during week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.

  • Mean Number of Puffs of Rescue Medication During Daytime (Last Week on Treatment, Response Values) [ Time Frame: Baseline and during week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.

  • Mean Number of Puffs of Rescue Medication During Nighttime (Last Week on Treatment, Response Values) [ Time Frame: Baseline and during week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.

  • Mean Number of Night Awakenings During the Last Week on Treatment (Score, Response Values) [ Time Frame: Baseline and during week 4 ] [ Designated as safety issue: No ]
    MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Assessed by the patient's electronic diary (eDiary incorporated in the AM2+ device), obtained during the last week of each period of randomised treatment.


Enrollment: 94
Study Start Date: July 2010
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tiotropium daily dose q.d.
two actuations delivered via Respimat® inhaler
Drug: Tiotropium 5 µg q.d.
5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
Experimental: Tiotropium half daily dose b.i.d.
two actuations delivered via Respimat® inhaler
Drug: Tiotropium 2.5 µg b.i.d
2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
Placebo Comparator: Placebo
N/A (two actuations of placebo) delivered via Respimat® inhaler
Drug: Placebo
N/A (two actuations of placebo) delivered via Respimat® inhaler

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. All patients must sign and date an Informed Consent Form consistent with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice ( ICH-GCP) guidelines and local legislation prior to participation in the trial (i.e. prior to any trial procedures, including any pre-trial washout of medications and medication restrictions for pulmonary function test at Visit 1).
  2. Male or female patients aged at least 18 years but not more than 75 years.
  3. All patients must have at least a 3 months history of asthma at the time of enrolment into the trial. The diagnosis of asthma has to be confirmed at Visit 1 with a bronchodilator reversibility resulting in a Forced Expiratory Volume in 1 Second (FEV1) increase of equal above 12% and equal above 200mL.
  4. The initial diagnosis of asthma must have been made before the patient's age of 40.
  5. All patients must have a diagnosis of moderate persistent asthma and must be symptomatic despite their current maintenance treatment with medium doses of inhaled corticosteroids.
  6. All patients must have been on maintenance treatment with a medium, stable dose of inhaled corticosteroids (alone or in a fixed combination with a Long Acting Betaadrenergic (LABA) or Short Acting Betaadrenergic (SABA)) for at least 4 weeks prior to Visit 1.
  7. All patients must be symptomatic at Visit 1 (screening) and Visit 2 as defined by an Asthma Control Questionnaire (ACQ) Score
  8. All patients must have a pre-bronchodilator FEV1 above equal 60% predicted and below equal 90% of predicted normal at Visit 1. Predicted normal values will be calculated according to the European Coal and Steel Community Guidelines (ECSC).
  9. All patients must have an increase in FEV1 of equal above 12% and equal above 200 mL 15 minutes after 400 µg salbutamol at Visit 1.
  10. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator) as compared to Visit 2 (pre-dose) must be within ± 30% .
  11. Patients must be never-smokers or ex-smokers who stopped smoking at least one year prior to enrolment and who have a smoking history of less than 10 pack years.
  12. Patients must be able to use the Respimat® inhaler correctly.
  13. Patients must be able to perform all trial related procedures including technically acceptable pulmonary function tests and use of the e-Diary/peak flow meter.
  14. Patients taking a chronic pulmonary medication allowed by the study protocol must be willing to continue this therapy for the entire duration of the study (exception: times of acute disease deterioration).

Exclusion criteria:

  1. Patients with a significant disease other than asthma.A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial.
  2. Patients with a clinically relevant abnormal screening hematology or blood chemistry if the abnormality defines a significant disease as defined in exclusion criterion no. 1.
  3. Patients with a recent history (i.e. six months or less) of myocardial infarction.
  4. Patients who have been hospitalised for cardiac failure during the past year.
  5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year.
  6. Patients with lung diseases other than asthma (e.g. Chronic Obstructive Lung Disease (COPD)).
  7. Patients with known active tuberculosis.
  8. Patients with malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.
  9. Patients who have undergone thoracotomy with pulmonary resection.
  10. Patients with significant alcohol or drug abuse within the past two years.
  11. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the 6 weeks prior to V 1.
  12. Patients with known hypersensitivity to anticholinergic drugs, Benzalconiumchloride (BAC), Ethylenediaminetetraacetate (EDTA) or any other components of the study medication delivery systems.
  13. Pregnant or nursing women.
  14. Women of childbearing potential not using a highly effective method of birth control.
  15. Patients who have been treated with beta-blocker medication within four weeks prior to Visit 1 or during the screening period. Topical cardio-selective beta-blocker eye medications for non-arrow angle glaucoma are allowed.
  16. Patients who have been treated with the long-acting anticholinergic tiotropium (Spiriva®) within four weeks prior to Visit 1 or during the screening period.
  17. Patients who have been treated with oral beta-adrenergics within four weeks prior to Visit 1 or during the screening period.
  18. Patients who have been treated with oral corticosteroids within four weeks prior to Visit 1 or during the screening period.
  19. Patients who have been treated with anti-IgE antibodies, e.g. omalizumab (Xolair®), within 6 months prior to Visit 1 or during the screening period.20. Patients who have been treated with cromolyn sodium or nedocromil sodium within two weeks prior to Visit 1 or during the screening period.

21. Patients who have been treated with methylxanthines within two weeks prior to Visit 1 or during the screening period.

22. Patients who have taken an investigational drug within four weeks prior to Visit 1.

23. Patients who have been treated with other non-approved and according to international guidelines not recommended "experimental" drugs for routine asthma therapy (e.g. TNFalpha blockers, methotrexate, cyclosporin) within four weeks prior to Visit 1 or during the screening period.

24. Patients with any asthma exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 or during the screening period. Visit 1 and/or Visit 2 should be postponed in case of an asthma exacerbation or respiratory tract infection.

25. Patients who have previously been randomised in this trial or are currently participating in another trial.

26.Patients who have been treated with depot corticosteroids within six months prior to Visit 1 or during the screening period.

27.Patients who have been treated with leukotriene modifiers within two weeks prior to Visit 1 or during the screening period.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01152450

Locations
Austria
205.420.43002 Boehringer Ingelheim Investigational Site
Linz, Austria
205.420.43004 Boehringer Ingelheim Investigational Site
Schlüsslberg, Austria
205.420.43003 Boehringer Ingelheim Investigational Site
Thalheim bei Wels, Austria
205.420.43001 Boehringer Ingelheim Investigational Site
Wels, Austria
Czech Republic
205.420.42002 Boehringer Ingelheim Investigational Site
Brno, Czech Republic
205.420.42001 Boehringer Ingelheim Investigational Site
Kyjov, Czech Republic
Estonia
205.420.37201 Boehringer Ingelheim Investigational Site
Kohtla-Järve, Estonia
205.420.37202 Boehringer Ingelheim Investigational Site
Tallinn, Estonia
Germany
205.420.49002 Boehringer Ingelheim Investigational Site
Großhansdorf, Germany
205.420.49004 Boehringer Ingelheim Investigational Site
Hannover, Germany
205.420.49001 Boehringer Ingelheim Investigational Site
Mannheim, Germany
205.420.49003 Boehringer Ingelheim Investigational Site
Schwerin, Germany
Latvia
205.420.37102 Boehringer Ingelheim Investigational Site
Daugavpils, Latvia
205.420.37101 Boehringer Ingelheim Investigational Site
Riga, Latvia
205.420.37103 Boehringer Ingelheim Investigational Site
Riga, Latvia
Sponsors and Collaborators
Boehringer Ingelheim
Pfizer
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01152450     History of Changes
Other Study ID Numbers: 205.420, 2009-018006-21
Study First Received: June 28, 2010
Results First Received: August 17, 2012
Last Updated: May 7, 2014
Health Authority: Austria: Federal Office for Safety in Health Care
Czech Republic: State Institute for Drug Control
Estonia: The State Agency of Medicine
Germany: Federal Institute for Drugs and Medical Devices
Latvia: State Agency of Medicines
United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Tiotropium
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014